Biogen just downgraded at Morgan Stanley, here's why - InvestingChannel

Biogen just downgraded at Morgan Stanley, here’s why

Morgan Stanley analyst Terence Flynn downgraded Biogen to Equal Weight from Overweight with a price target of $204, down from $285. The firm says the Leqembi launch has tracked below its expectations while it sees see “limited pipeline optionality” over the next 12 months. Morgan Stanley admits that it underestimated initial reimbursement and logistical headwinds for Leqembi. It sees a balanced risk/reward for Biogen and a more measured outlook for lecanemab.

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire